Qyuns Therapeutics (2509.HK)

Executive Summary

Qyuns Therapeutics is a China-based biotech company specializing in antibody therapeutics for autoimmune and allergic diseases. Leveraging its proprietary rabbit antibody development platform, the company has built a pipeline targeting key inflammatory pathways including IL-4Rα, IL-17A, IL-23, and TSLP. Its lead candidate, QY-202 (anti-IL-4Rα), is in Phase 2 trials for atopic dermatitis, while QY-101 (anti-IL-17A) is advancing in plaque psoriasis. The company went public on the Hong Kong Stock Exchange (ticker: 2509.HK) with a market valuation of approximately $4 billion, reflecting investor confidence in its novel platform and large addressable market. Recent progress includes positive preliminary efficacy data from Phase 2 studies and ongoing patient enrollment. Qyuns is well-positioned to address the growing demand for innovative biologics in China and globally, with the autoimmune and allergy treatment market expanding rapidly. Key upcoming milestones include data readouts for its lead candidates and potential partnership opportunities for its TSLP program. While execution risks remain, the company's strong science and focused pipeline provide a solid foundation for near-term value creation.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Data Readout for QY-202 (IL-4Rα) in Atopic Dermatitis70% success
• Q1 2027Initiation of Phase 3 Trial for QY-101 (IL-17A) in Plaque Psoriasis80% success
• TBDPotential Out-Licensing Deal for TSLP Antibody Program30% success